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Illicit use of performance-enhancing steroids has proliferated among a wide range of professional and amateur
athletes.This problem has attracted broad public attention and has led the United States Congress to draft
legislation that proposes frequent testing of athletes. However, current testing protocols are inadequate as
athletes can evade detection by using novel steroids that are unknown to authorities.We have developed a
strategy that overcomes this limitation by virtue of its ability to detect “designer steroids” without prior
knowledge of their existence.
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Introduction
The use of performance-enhancing drugs has proliferated
among elite professional athletes, Olympians and even
high-school amateurs. Use of these agents are of
particular concern as they are administered in the
absence of the type of efficacy and safety testing that
would be required for FDA approval.Thus, the ongoing
abuse of these potentially toxic agents has aroused
widespread public attention. On October 22, 2004,
President George W. Bush signed the Anabolic Steroids
Control Act into federal law.This act extended the
definition of anabolic steroids to include “any drug or
hormonal substance, chemically and pharmacologically
related to testosterone”. As a result, compounds that meet
this definition are now considered a controlled substance
under federal law. Continued abuse by professional
athletes and others has prompted two separate
Congressional committees to draft additional legislation
that is further aimed at curtailing this problem. If passed
into law, the Clean Sports Act (HR 2565) and the
Drug-Free Sports Act (HR 1862) would mandate recurrent
testing of professional athletes and would impose
extended suspensions or lifelong bans for those who test
positive [USHR, 2005].
The success of this legislation and/or other interventions
assumes the availability of robust screens that can detect
the presence of all performance-enhancing drugs. In the
case of anabolic steroids, current approaches utilize
sensitive assays such as GC/MS or ELISA to detect the
presence of known steroids in biological samples.These
assays suffer from a severe limitation: they require
pre-existing knowledge of the precise compounds that
are being abused. An athlete can evade detection by
using an anabolic steroid that is not known to authorities
[Handelsman, 2004] . Indeed, an emerging clandestine
industry has allowed athletes to evade detection via the
use of novel “designer steroids”. Several test-evading
designer steroids have been identified in the past 3 years
including two existing compounds that were never
marketed [Sekera et al., 2005] and a novel chemical entity
that was specifically synthesized to evade detection
(tetrahydrogestrinone, THG) [Catlin et al., 2004] .The
latter drug has been implicated in the BALCO
investigation.
Anabolic steroids function by binding to the nuclear
androgen receptor (AR) [Handelsman, 2004] . A
bewildering array of diverse synthetic ligands have been
identified for AR and other nuclear receptors [Buijsman
et al., 2005] and hundreds-to-thousands of never
marketed AR ligands have been described in the patent
and scientific literature. Moreover, existing
high-throughput screening strategies could allow rogue
scientists to produce additional designer steroids. It is
possible that test-evading steroids are currently in use
as these compounds cannot be identified until a
“whistle-blower” steps forward and provides suspect
samples to the authorities. It is evident that novel
strategies must be developed that can detect illicit steroids
without prior knowledge of their chemical structure.
Reagents and Instruments
Gas chromatography/mass-spectrometry
(GC/MS)
A ThermoFinnigan Trace DSQ GC/MS system was used
for these studies. Gas chromatographic separation was
performed with a Phenomenex ZB-5 (5% phenyl-95%
dimethyl-polysiloxane) column (15 meters, 0.25 mm ID,
film thickness 0.50 µm). Following data acquisition, total
ion spectra found in the samples were compared to known
spectra contained in the NIST 98 Library using the
Finnigan Xcalibur software.
Methods
Isolation and identification of anabolic steroids
A single lot of normal human male serum (Gemini
cat#100-512, Lot# H01904Y) and a single lot of normal
human female serum (Gemini cat#100-110F, Lot#
H00903Y) were used throughout these experiments in
order to exclude interindividual differences as a source
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0.1-10 nM nandrolone (Steraloids cat# E4050-000),
0.1-10 nM methandienone (Steraloids cat# A0130-020)
and in some cases female serum was adjusted to contain
concentrations of testosterone (T, 15 nM) and
dihydrotestosterone (DHT, 3 nM) that are within the range
normally present in healthy adult men [Griffen and Wilson,
1998] . For analysis, serum (2.5 ml) was extracted
two-times with 2 volumes of ethyl acetate.The two ethyl
acetate fractions were pooled, washed twice with water
and then dried under nitrogen.
Figure 1. Detection of anabolic steroids in female serum. (a)
Normal human female serum spiked with T (15 nM) and DHT (3 nM) was
extracted and incubated with control (black line) or AR-containing beads
(red line). Eluates were analyzed by GC/MS and the chromatograms were
overlaid.The peaks corresponding to DHT (11.37 min) and T (11.67 min)
were confirmed by comparing elution times and mass spectra with known
standards. (b) Female serum containing 15nM T, 3 nM DHT and 1 nM
(0.27 ng/ml) nandrolone was analyzed as in (a).The elution time and
mass spectrum of the 11.42 min. peak is indistinguishable from
nandrolone.
The steroid-screening assay was performed by incubating
the ethyl acetate fraction with agarose-bound androgen
receptor ligand binding domain (AR).To do so,
thioredoxin-linked AR (~30 µg total protein; specific
activity 2.2 pmol bound ligand/µg, Invitrogen) was
incubated with 40 µl Ni-NTA agarose (50% slurry) in a
total volume of 300 µl of buffer A (20mM Tris, pH 8,
500mM NaCl, 5mM imidazole) at 4 °C for 1 hr. Ni-NTA
beads were pelleted and washed once with 1 ml of ligand
binding buffer (30 mM Tris pH 8.0, 150 mM KCl) then
resuspended in 300 µl of ligand binding buffer containing
0.4 mg/ml ovalbumin. Immediately prior to assay, the
dried ethyl acetate serum fraction was dissolved in 2 ml
of ligand binding buffer by incubating for 30 min at room
temperature and then incubated with the immobilized AR
beads for 1 hr at room temperature followed by 1 hr at 4
°C. Immobilized AR was then pelleted and washed once
with 2 ml ligand binding buffer to remove any unbound
ligand.To dissociate the bound ligands from receptor,
immobilized AR was incubated for 30 min. at 65 °C in
400 µl PBS and the released ligands were collected in
the supernatant.This elution was repeated and the two
PBS- fractions were pooled, filtered through a 0.22 µm
PTFE filter, and extracted two-times with 3-volumes of
ethyl acetate.The organic phases were pooled and dried
under nitrogen.
The dried samples were derivatized with 20 µl of N,O -bis
(trimethylsilyl) trifluoroacetamide containing 1%
trimethylchlorosilane (Pierce) at 55 °C for 6 hr, then 4 µl
were analyzed by GC/MS run in scanning mode over a
M/Z range of 50-700. At the start of each run, the column
temperature was held at 50 °C for 1 minute, increased
using a gradient of 25 °C /min up to 300 °C, and held at
300 °C for an additional 8 minutes.
Results
We sought to develop a novel strategy to detect illicit
steroids without prior knowledge of their chemical
structure.To be useful in an anti-doping setting, these
assays must also distinguish illicit androgens from their
naturally occurring counterparts: testosterone (T) and
dihytdrotestosterone (DHT).To address this need, we
sought to establish a sensitive assay that identifies
anabolic steroids by virtue of their ability to bind to their
pharmacologic target, AR.We then analyze the bound
ligands by GC/MS which distinguishes the illicit drug from
endogenous androgens.This strategy is distinct from
existing strategies as detection is based on AR-binding
activity, as opposed to chemical identity.
Our proposed strategy cannot be tested with actual
samples due to legal restrictions on banned substances
and the obvious difficulties in obtaining specimens from
athletes who are actively in violation of competitive
guidelines. Instead, we performed a proof-of-principle
experiment using nandrolone (4-estren-17β-ol-3-one)
[Holterhus et al., 2002] , a commercially available anabolic
steroid that is prohibited by the World Anti-Doping Agency
(WADA), the National Collegiate Athletic Association
(NCAA) and by Anabolic Steroids Control Act of 2004.
Human female serum was adjusted to contain
concentrations of testosterone (T, 15 nM) and
dihydrotestosterone (DHT, 3 nM) that are within the range
normally present in healthy adult men [Griffen and Wilson,
1998] .This test serum was then incubated with
agarose-bound AR or control beads.The beads were
collected, washed and AR-bound ligands were eluted
and analyzed by GC/MS. As expected, peaks
corresponding to DHT (11.37 min) and T (11.67 min) were
detected when using AR, but not with control beads
(Figure 1a) or beads linked to estrogen receptor α (data
not shown). It is important to note that no other
endogenous steroids (e.g. glucocorticoids, estrogens,
progestins, mineralocorticoids, etc.) were detected with
AR despite the presence of these steroids in normal
serum. Furthermore, AR failed to detect the presence of
17β-estradiol even when excess quantities of this steroid
(10 nM) were intentionally spiked into the serum (data
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that the proposed strategy selectively identifies natural
androgens from the diverse background of endogenous
compounds that are present in normal human serum.
Figure 2. Detection of anabolic steroids in male serum. (a) Normal
human male serum was extracted and incubated with control (black line)
or AR-containing beads (red line). Eluates were analyzed by GC/MS and
the chromatograms were overlaid.The peaks corresponding to
endogenous DHT (11.37 min) and T (11.67 min) were confirmed by
comparing elution times and mass spectra with known standards. (b)
Male serum containing 1 nM (0.27 ng/ml) nandrolone was analyzed as
in (a).The elution time and mass spectrum of the 11.42 min. peak is
indistinguishable from nandrolone. (c) Male serum containing 1 nM (0.30
ng/ml) methandienone was analyzed as in (a).The elution time and mass
spectrum of the 12.32 min. peak is indistinguishable from methandienone.
A separate experiment was performed to determine if this
approach could be used to identify banned steroids.
Female serum with T & DHT was spiked with 1 nM (0.27
ng/ml) nandrolone to mimic a “tainted” serum sample. As
described below, 1 nM represents a very low
concentration of drug – i.e., a concentration that is below
the detection limits established for doping-controls labs.
This low concentration was intentionally selected in order
to examine the sensitivity of the assay.When this “tainted”
sample was tested, an additional AR-specific peak (Figure
1b, 11.42 min) was identified that does not correspond
to endogenous androgens (Figure 1a). Since this material
binds AR but does not correspond to the endogenous
androgens, one can conclude an illicit steroid is present
in this sample.
In order to further validate the assay, we performed similar
experiments using normal male serum. As expected, AR
specifically captured endogenous T and DHT from normal
male serum (Figure 2a). Since the serum used in this
experiment was not modified in any way, this analysis
further demonstrates that our assay is very robust, i.e. it
can easily identify the physiological levels of endogenous
androgens that are normally present in male serum.
To confirm that illicit steroids can also be identified in
male serum, we asked whether we could identify a foreign
peak in male serum that had been tainted by addition of
1 nM nandrolone. As was the case for female serum,
when this “tainted” sample was tested, an additional
AR-specific peak (Figure 2b, 11.42 min) was identified
that is distinct from the endogenous androgens seen in
normal serum (Figure 2a).The presence of a foreign peak
that specifically bound to AR leads to the conclusion that
an illicit anabolic steroid is present.
To further extend the usefulness of this approach, we
asked whether our assay could detect other anabolic
steroids. Methandienone (metandienone, dianabol,
17β-hydroxy-17α-methylandrosta-1,4-dien-3-one)
provides an example of another commercially available
steroid that is banned by WADA and the NCAA and
controlled by the Anabolic Steroids Control Act of 2004.
Again, very low concentrations of the drug (1 nM, 0.30
ng/ml) were intentionally used in order to challenge the
sensitivity limits of the assay. As seen in Figure 2c, a
foreign peak (12.32 min) is also detected in normal male
serum spiked with 1 nM methandienone.Thus, our assay
can detect low levels of several anabolic steroids that are
banned by major athletic oversight agencies.
The ability to easily detect endogenous androgens in
normal male serum (Figure 2a-c) indicates that our assay
has sufficient sensitivity to detect biologically relevant
concentrations of androgens. As a further test of our
assay, we wished to determine whether our assay detects
pharmacologically relevant concentrations of illicit
steroids.WADA has established minimum required
performance limits for doping-control laboratories [World
Anti-Doping Agency, 2004] . For most anabolic steroids
this detection limit is set at 10 ng/ml (~33 nM) though a
lower detection limit of 2 ng/ml (6.6 nM) has been
established for methandienone and several other steroids.
The data in Figures 1-2 demonstrate that we can detect
nandrolone and methandienone at concentrations of 1
nM which is 6-30 fold lower than the minimum limits
prescribed by WADA.To further quantify the sensitivity
of our assay, we spiked normal female serum with 0.1,
1 and 10 nM concentrations of nandrolone and
methandienone and examined our ability to detect the
captured steroid. Figure 3 represents a plot of the peak
area versus the concentration of illicit steroid. Although
we were unable to detect 0.1 nM (0.030 ng/ml)
methandienone, we could detect peaks for all other
concentrations including 0.1 nM (0.027 ng/ml) nandrolone.
The 0.1 nM nandrolone peak was at the very lower limit
of detection suggesting that a more practical detection
limit for nandrolone is somewhere between 0.1 and 1 nM
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sensitivity of our assay is over 33-fold greater than WADA
requirements and at least 6-fold greater for
methandienone.
Figure 3. Sensitivity of anabolic steroid detection. Normal female
serum was spiked with 0.1-10 nM (0.027 - 2.74 ng/ml) nandrolone or with
0.1-10 nM (0.030-3.00 ng/ml) methandienone and analyzed as in Figure
1a.The peaks areas corresponding to nandrolone (11.42 min) and
methandienone (12.32 min) are plotted vs. steroid concentration.
A recent survey has suggested that athletes may resort
to polypharmacy when abusing steroids [Perry et al.,
2005] .This prompted to us ask whether our assay could
simultaneously detect two banned substances in a single
sample. In principle, detection of multiple substances
should be possible provided that the amount of AR in the
assay is sufficiently high relative to the total androgen
pool in the tainted sample.The final concentration of
active AR in our assay is 29 nM (see Methods).This
concentration is higher than the low nanomolar
concentrations of steroids that would typically be present
in our assay conditions.To examine this situation
experimentally, we spiked normal female serum (Figure
4a) and normal male serum (Figure 4b) with 1 nM of both
nandrolone and methandienone and asked whether two
foreign peaks could be identified in an AR-specific
manner. In both cases, the assay was able to detect the
presence of foreign peaks that do not correspond to the
endogenous androgens.These data further demonstrate
the utility of our assay in detecting small amounts of illicit
steroids from both male and female serum.
Many anabolic steroids like nandrolone and
methandienone possess high affinity (low nanomolar) for
the androgen receptor [Holterhus et al., 2002] . As with
other steroid-related drugs, higher affinity AR ligands
would generally be preferred pharmaceutical agents as
they are less likely to bind to and modulate other related
nuclear receptors. Nonetheless, it remains possible that
lower affinity designer steroids could potentially be
introduced to athletes. As a final test of our assay we
asked whether a lower affinity compound could be
detected. Previous studies have shown that
5α-androstan-3α,17β-diol can activate AR though high
concentrations (1 µM) are required for maximal activation
[Forman et al., 1998] . As shown in Figure 5, our assay
could successfully detect the presence of 1 µM
5α-androstan-3α,17β-diol in male serum.Thus, even
lower affinity AR ligands can be detected by this
methodology.
Figure 4. Simultaneous detection of multiple anabolic steroids.
(a) Normal female serum was simultaneously spiked with 1 nM nandrolone
(0.27 ng/ml) and 1 nM methandienone (0.30 ng/ml) and analyzed as in
Figure 1a. (b) Normal male serum spiked as in (a).The peaks
corresponding to nandrolone (11.42 min) and methandienone (12.32 min)
are noted. Control beads: black line; AR-containing beads: red line.
Discussion
The above findings demonstrate the unique utility of our
strategy relative to current steroid testing strategies.
Existing approaches screen serum samples for known
chemical substances. As a result, athletes can effectively
evade the current testing regimens by utilizing novel
compounds that are not yet known to the authorities.The
demand for such material has spawned a rogue
pharmaceutical industry whose sole purpose is to supply
athletes with anabolic steroids that go under the radar of
existing detection strategies.
Figure 5. Detection of low affinity anabolic steroids. Normal male
serum was spiked with 1 µM 5α-androstan-3α,17β-diol and analyzed as
in Figure 1-2. Peaks corresponding to DHT (11.37 min), T (11.67 min)
and 5α-androstan-3α,17β-diol (11.02 min) are noted. Control beads: black
line; AR-containing beads: red line.
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successful.The availability of high-throughput AR-ligand
screens and a vast scientific and patent literature on
androgenic steroids, raises legitimate concern that other
novel compounds could currently be in use, while others
may be developed in the future. Indeed, the full-extent of
the current problem is not fully known because the only
designer compounds that can be identified are those
where there was a “whistle-blower” who alerted
authorities. Even in cases where such individuals exist
and are willing to step forward, chemical characterization
of the new steroid can only be accomplished if these
individuals have access to fairly large quantities of
relatively pure material. It is clear that a new strategy is
required that can efficiently detect the levels of novel
anabolic steroids that would be present in the biological
fluids of abusing athletes. Furthermore, for such a strategy
to be effective it must be able to distinguish synthetic and
natural steroids and it must also detect the synthetic
steroids without prior knowledge of their chemical
structure.
The technique we present addresses these requirements.
Rather than searching for the chemical signatures of
known anabolic steroids, our approach identifies the illicit
drug by virtue of its ability to bind AR.We could
successfully detect pharmacologically relevant
concentrations of nandrolone and methandienone in a
background of normal human serum; detection limits were
well within the 2-10 ng/ml range specified by WADA. For
other compounds, the precise sensitivity of our approach
will vary depending on the compound, the extraction
scheme and/or the separation technique utilized (e.g.
LC/MS vs. GC/MS). Nonetheless, our approach is likely
to be of general utility as these same analytical
techniques, and their corresponding limitations, are
routinely applied toward the identification of known
steroids in sample specimens.Thus, our strategy is likely
to have an appropriate range of sensitivity for many
compounds, but with the added value of detecting
unknown steroids.
It should be noted that our assay is only designed to
detect AR-binding compounds: it is not designed to detect
inactive pro-drugs.This is unlikely to be a practical
limitation as biological activity requires that sufficient
quantities of the pro-drug be converted into the
biologically active AR-binding compound.Thus, while our
assay would miss the pro-drug, the data provided suggest
that it would detect the active metabolite.
Our designer steroid assay deserves further consideration
and/or field-testing as it has implications for emerging
anti-doping legislation and for international athletic testing
guidelines.This assay may also have utility for testing
dietary supplements that may potentially contain designer
steroids as undeclared ingredients [Maughan, 2005; Parr
et al., 2004] .
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